Alligator Bioscience enters into research and option agreement with BioInvent to jointly develop Antibody-based therapeutics

18-Sep-2009 - Sweden

Alligator Bioscience AB today announced a research and option agreement with BioInvent International AB to co-develop an antibody-based drug for oncology indications.

This collaboration combines the strengths of both companies' technologies to develop a next generation immunotherapeutic treatment that could provide systemic anti-cancer effect and immunity, with minimal systemic side effects for the benefit of cancer patients.

Dr Gun-Britt Fransson, Chief Executive Officer of Alligator Bioscience, commented: "We are very pleased to work with BioInvent, a company with proven success in developing antibody-based drugs, and we believe that Alligator Biosciences technology and know-how will add a substantial value and success to this joint program. Further, it also confirms that Alligator Biosciences technology is valuable and needed for the development of next generation antibody based drugs". According to the terms, the parties will after an initial research phase share costs and revenues equally.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance